{"id":71777,"date":"2026-08-06T00:30:59","date_gmt":"2026-08-05T16:30:59","guid":{"rendered":"https:\/\/flcube.com\/?p=71777"},"modified":"2026-08-06T00:31:00","modified_gmt":"2026-08-05T16:31:00","slug":"cspc-pharmaceuticals-nda-for-anbenitamab-hb1801-combination-accepted-by-china-nmpa-as-neoadjuvant-therapy-for-her2-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71777","title":{"rendered":"CSPC Pharmaceutical&#8217;s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that the <strong>New Drug Application (NDA)<\/strong> for its subsidiary <strong>JMT-Bio&#8217;s anbenitamab (KN026)<\/strong>\u2014co-developed with <strong>Alphamab Oncology<\/strong> (9966.HK)\u2014in combination with the Group&#8217;s proprietary <strong>docetaxel for injection (albumin-bound) (HB1801)<\/strong> as a <strong>neoadjuvant therapy<\/strong>, has been <strong>accepted by China&#8217;s National Medical Products Administration (NMPA)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td><strong>Product Combination<\/strong><\/td><td>Anbenitamab (KN026) + HB1801<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Neoadjuvant therapy (specific indication not disclosed, likely HER2+ breast cancer based on prior approvals)<\/td><\/tr><tr><td><strong>Development Partnership<\/strong><\/td><td>Co-developed with Alphamab Oncology<\/td><\/tr><tr><td><strong>Current Status<\/strong><\/td><td>Anbenitamab already approved and launched in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-anbenitamab-kn026\" class=\"wp-block-heading\">Anbenitamab (KN026)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type<\/strong>: Bispecific HER2 antibody<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Simultaneously binds two non-overlapping epitopes of HER2<\/li>\n\n\n\n<li><strong>Key Actions<\/strong>:<\/li>\n\n\n\n<li>Blocks HER2 signaling<\/li>\n\n\n\n<li>Enhances HER2 internalization<\/li>\n\n\n\n<li>Downregulates HER2 expression<\/li>\n\n\n\n<li>Retains Fc-mediated ADCC (antibody-dependent cellular cytotoxicity) activity<\/li>\n\n\n\n<li><strong>Development Status<\/strong>: Already approved and commercially available in China<\/li>\n\n\n\n<li><strong>Partnership<\/strong>: Co-developed with Alphamab Oncology<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-hb1801-docetaxel-albumin-bound\" class=\"wp-block-heading\">HB1801 (Docetaxel Albumin-Bound)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform<\/strong>: CSPC&#8217;s proprietary nanomedicine technology platform<\/li>\n\n\n\n<li><strong>Formulation<\/strong>: Docetaxel encapsulated in human serum albumin<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: Representative drug from CSPC&#8217;s advanced drug delivery pipeline<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-hb1801-clinical-advantages-vs-conventional-docetaxel\" class=\"wp-block-heading\">HB1801 Clinical Advantages vs. Conventional Docetaxel<\/h2>\n\n\n\n<h3 id=\"h-enhanced-safety-and-compliance\" class=\"wp-block-heading\">Enhanced Safety and Compliance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Allergic Reaction Elimination<\/strong>: No hypersensitivity reactions compared to conventional docetaxel<\/li>\n\n\n\n<li><strong>Premedication Removal<\/strong>: Eliminates need for corticosteroid premedication<\/li>\n\n\n\n<li><strong>Administration Flexibility<\/strong>: Enables rapid, high-concentration administration<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-superior-efficacy-profile\" class=\"wp-block-heading\">Superior Efficacy Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Anti-Tumor Activity<\/strong>: Preclinical and clinical studies demonstrate significant tumor suppression<\/li>\n\n\n\n<li><strong>Dosing Advantage<\/strong>: Allows for higher clinical dosing to maximize therapeutic response<\/li>\n\n\n\n<li><strong>Therapeutic Index<\/strong>: Improved safety profile enables more aggressive treatment regimens<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-cspc-pharmaceutical\" class=\"wp-block-heading\">Strategic Implications for CSPC Pharmaceutical<\/h2>\n\n\n\n<h3 id=\"h-portfolio-diversification\" class=\"wp-block-heading\">Portfolio Diversification<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Expansion<\/strong>: Strengthens position in high-value cancer therapeutics market<\/li>\n\n\n\n<li><strong>Combination Strategy<\/strong>: Leverages existing approved product (anbenitamab) with novel delivery system (HB1801)<\/li>\n\n\n\n<li><strong>Technology Validation<\/strong>: Demonstrates success of CSPC&#8217;s nanomedicine platform<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-advantages\" class=\"wp-block-heading\">Commercial Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Differentiation<\/strong>: Unique combination offering enhanced safety and efficacy<\/li>\n\n\n\n<li><strong>Pricing Power<\/strong>: Premium positioning supported by clinical advantages over standard regimens<\/li>\n\n\n\n<li><strong>Competitive Moat<\/strong>: Proprietary HB1801 formulation creates barrier to generic competition<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-partnership-synergy\" class=\"wp-block-heading\">Partnership Synergy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Risk Sharing<\/strong>: Co-development model with Alphamab Oncology optimizes resource allocation<\/li>\n\n\n\n<li><strong>Commercial Rights<\/strong>: Likely favorable economics for CSPC given HB1801 ownership and JMT-Bio subsidiary structure<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Success in China may support future international regulatory submissions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 id=\"h-her2-cancer-market\" class=\"wp-block-heading\">HER2+ Cancer Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High Unmet Need<\/strong>: Significant patient population requiring effective neoadjuvant therapies<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Conventional docetaxel-based regimens with safety limitations<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: HB1801&#8217;s safety profile addresses key treatment barriers<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-nanomedicine-platform\" class=\"wp-block-heading\">Nanomedicine Platform<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Leadership<\/strong>: Positions CSPC as innovator in advanced drug delivery<\/li>\n\n\n\n<li><strong>Pipeline Potential<\/strong>: HB1801 success validates platform for other oncology compounds<\/li>\n\n\n\n<li><strong>Investment Attraction<\/strong>: Demonstrates capability to develop differentiated products beyond generics<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-development-amp-commercial-outlook\" class=\"wp-block-heading\">Forward Development &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Timeline<\/strong>: Priority review possible given combination of approved product with novel delivery system<\/li>\n\n\n\n<li><strong>Market Access<\/strong>: Expected inclusion in national reimbursement negotiations upon approval<\/li>\n\n\n\n<li><strong>Physician Adoption<\/strong>: Enhanced safety profile likely to drive rapid clinical adoption<\/li>\n\n\n\n<li><strong>Launch Preparation<\/strong>: Existing commercial infrastructure for anbenitamab facilitates combination rollout<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical advantages, and commercial potential. Actual outcomes may differ due to risks including final regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080401597_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026080401597_c.\"><\/object><a id=\"wp-block-file--media-eacfe5e8-88f4-410f-8f34-f1db9208ed73\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080401597_c.pdf\">2026080401597_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080401597_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-eacfe5e8-88f4-410f-8f34-f1db9208ed73\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[29,171,83,855,38],"class_list":["post-71777","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-combination-therapy","tag-cspc-pharmaceutical","tag-her2","tag-hkg-1093","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical&#039;s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its subsidiary JMT-Bio&#039;s anbenitamab (KN026)\u2014co-developed with Alphamab Oncology (9966.HK)\u2014in combination with the Group&#039;s proprietary docetaxel for injection (albumin-bound) (HB1801) as a neoadjuvant therapy, has been accepted by China&#039;s National Medical Products Administration (NMPA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71777\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical&#039;s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its subsidiary JMT-Bio&#039;s anbenitamab (KN026)\u2014co-developed with Alphamab Oncology (9966.HK)\u2014in combination with the Group&#039;s proprietary docetaxel for injection (albumin-bound) (HB1801) as a neoadjuvant therapy, has been accepted by China&#039;s National Medical Products Administration (NMPA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71777\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T16:30:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-05T16:31:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71777#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71777\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical&#8217;s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer\",\"datePublished\":\"2026-08-05T16:30:59+00:00\",\"dateModified\":\"2026-08-05T16:31:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71777\"},\"wordCount\":526,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Combination therapy\",\"CSPC Pharmaceutical\",\"HER2\",\"HKG: 1093\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71777#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71777\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71777\",\"name\":\"CSPC Pharmaceutical's NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-05T16:30:59+00:00\",\"dateModified\":\"2026-08-05T16:31:00+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its subsidiary JMT-Bio's anbenitamab (KN026)\u2014co-developed with Alphamab Oncology (9966.HK)\u2014in combination with the Group's proprietary docetaxel for injection (albumin-bound) (HB1801) as a neoadjuvant therapy, has been accepted by China's National Medical Products Administration (NMPA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71777#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71777\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71777#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical&#8217;s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical's NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its subsidiary JMT-Bio's anbenitamab (KN026)\u2014co-developed with Alphamab Oncology (9966.HK)\u2014in combination with the Group's proprietary docetaxel for injection (albumin-bound) (HB1801) as a neoadjuvant therapy, has been accepted by China's National Medical Products Administration (NMPA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71777","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical's NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its subsidiary JMT-Bio's anbenitamab (KN026)\u2014co-developed with Alphamab Oncology (9966.HK)\u2014in combination with the Group's proprietary docetaxel for injection (albumin-bound) (HB1801) as a neoadjuvant therapy, has been accepted by China's National Medical Products Administration (NMPA).","og_url":"https:\/\/flcube.com\/?p=71777","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-05T16:30:59+00:00","article_modified_time":"2026-08-05T16:31:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71777#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71777"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical&#8217;s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer","datePublished":"2026-08-05T16:30:59+00:00","dateModified":"2026-08-05T16:31:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71777"},"wordCount":526,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Combination therapy","CSPC Pharmaceutical","HER2","HKG: 1093","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71777#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71777","url":"https:\/\/flcube.com\/?p=71777","name":"CSPC Pharmaceutical's NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-05T16:30:59+00:00","dateModified":"2026-08-05T16:31:00+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its subsidiary JMT-Bio's anbenitamab (KN026)\u2014co-developed with Alphamab Oncology (9966.HK)\u2014in combination with the Group's proprietary docetaxel for injection (albumin-bound) (HB1801) as a neoadjuvant therapy, has been accepted by China's National Medical Products Administration (NMPA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71777#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71777"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71777#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical&#8217;s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71777"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71777\/revisions"}],"predecessor-version":[{"id":71779,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71777\/revisions\/71779"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}